Johnson, Douglas B.

T cells specific for α-myosin drive immunotherapy-related myocarditis

Axelrod, M. L., Meijers, W. C., Screever, E. M., Qin, J., Carroll, M. G., Sun, X., Tannous, E., Zhang, Y., Sugiura, A., Taylor, B. C., et al. (2022) · Nature

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 367

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 367

Immune checkpoint inhibitors in challenging populations

Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 339

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 338

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 290

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J.-E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersAutoimmune Neurological Disorders and Treatments

Cited by 176

Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis

Lehmann, L. H., Heckmann, M. B., Bailly, G., Finke, D., Procureur, A., Power, J. R., Stein, F., Bretagne, M., Ederhy, S., Fenioux, C., et al. (2023) · Circulation

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 165

Treatment of NRAS-mutant melanoma

Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 139

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research

Chemotherapy-induced cardiotoxicity and mitigationCancer Immunotherapy and Biomarkers

Cited by 138

Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis

Grouthier, V., Lebrun-Vignes, B., Moey, M., Johnson, D. B., Moslehi, J. J., Salem, J.-E., & Bachelot, A. (2020) · The Oncologist

Cancer Immunotherapy and BiomarkersAdrenal Hormones and Disorders

Cited by 126

Harnessing big data to characterize immune-related adverse events

Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 125

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersImmunotoxicology and immune responses

Cited by 118

Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

Quach, H. T., Dewan, A. K., Davis, E. J., Ancell, K. K., Fan, R., Ye, F., & Johnson, D. B. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 107

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

Johnson, D. B., Friedman, D. L., Berry, E., Decker, I., Ye, F., Zhao, S., Morgans, A. K., Puzanov, I., Sosman, J. A., & Lovly, C. M. (2015) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 101

On the cusp: considering the impact of artificial intelligence language models in healthcare

Goodman, R. S., Patrinely, J. R., Osterman, T., Wheless, L., & Johnson, D. B. (2023) · Med

Artificial Intelligence in Healthcare and EducationMachine Learning in Healthcare

Cited by 100

A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Xia, J., Jia, P., Hutchinson, K. E., Dahlman, K. B., Johnson, D., Sosman, J., Pao, W., & Zhao, Z. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 94

Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow

Roussel, M., Ferrell, P. B., Greenplate, A. R., Lhomme, F., Le Gallou, S., Diggins, K. E., Johnson, D. B., & Irish, J. M. (2017) · Journal of Leukocyte Biology

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 93

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program

Naqash, A. R., Moey, M. Y. Y., Cherie Tan, X.-W., Laharwal, M., Hill, V., Moka, N., Finnigan, S., Murray, J., Johnson, D. B., Moslehi, J. J., et al. (2022) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigation

Cited by 87

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Fenioux, C., Abbar, B., Boussouar, S., Bretagne, M., Power, J. R., Moslehi, J. J., Gougis, P., Amelin, D., Dechartres, A., Lehmann, L. H., et al. (2023) · Nature Medicine

Cancer Immunotherapy and BiomarkersMyasthenia Gravis and Thymoma

Cited by 83

Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling

Siska, P. J., Johnpulle, R. A. N., Zhou, A., Bordeaux, J., Kim, J. Y., Dabbas, B., Dakappagari, N., Rathmell, J. C., Rathmell, W. K., Morgans, A. K., et al. (2017) · OncoImmunology

Testicular diseases and treatmentsCancer Immunotherapy and Biomarkers

Cited by 82

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 75

Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy

Shah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B. (2020) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 64

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersCancer survivorship and care

Cited by 61

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma

Giricz, O., Mo, Y., Dahlman, K. B., Cotto-Rios, X. M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D. B., et al. (2018) · JCI Insight

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 40